Department of Radiation Oncology, Fondazione di Ricerca e Cura "Giovanni Paolo II", Università Cattolica del S. Cuore, Largo A. Gemelli 1, 86100, Campobasso, Italy.
Radiol Med. 2014 May;119(5):343-7. doi: 10.1007/s11547-013-0346-z. Epub 2013 Dec 6.
This study was done to assess the impact of clinical factors and in particular the use of drugs for concomitant illnesses on late radiation-induced rectal bleeding in patients with prostate cancer.
Patients with histologically proven prostate adenocarcinoma treated with radical radiotherapy and followed up for at least 6 months were selected. The correlation between late rectal bleeding and a number of factors was investigated by univariate and multivariate analysis.
A total of 278 patients who underwent radiotherapy at our institution between October 2002 and May 2011 were selected. At univariate analysis, delivery of radiation doses higher than 70 Gy and use of angiotensin-converting enzyme inhibitors were associated with a higher incidence of rectal bleeding. Conversely, patients who used calcium channel blockers had a lower risk (3-year rectal bleeding-free survival 89.8 versus 66.5 %, p = 0.043). At multivariate analysis, use of calcium channel blockers was found to have a protective effect with a hazard ratio of 0.3 (95 % CI 0.12-0.96). Delivery of higher radiation doses was associated with an increased risk of rectal bleeding (hazard ratio 3.02, 95 % CI 1.23-7.38).
Use of calcium channel blockers during and after radiotherapy treatment might have a protective effect against late rectal bleeding. If these results are reconfirmed by larger clinical series, calcium channel blockers may be tested as radioprotector agents in clinical trials.
本研究旨在评估临床因素,尤其是合并症治疗药物的使用对前列腺癌患者放疗后迟发性直肠出血的影响。
选择了 278 名在我院接受根治性放疗且随访至少 6 个月的组织学证实的前列腺腺癌患者。通过单因素和多因素分析研究迟发性直肠出血与多种因素的相关性。
在我院接受放疗的 278 名患者中,单因素分析显示,接受高于 70Gy 的放射剂量和使用血管紧张素转换酶抑制剂与较高的直肠出血发生率相关。相反,使用钙通道阻滞剂的患者风险较低(3 年直肠出血无进展生存率为 89.8% vs. 66.5%,p=0.043)。多因素分析发现,使用钙通道阻滞剂具有保护作用,风险比为 0.3(95%CI 0.12-0.96)。较高的放射剂量与直肠出血风险增加相关(风险比 3.02,95%CI 1.23-7.38)。
放疗期间和之后使用钙通道阻滞剂可能对迟发性直肠出血具有保护作用。如果这些结果在更大的临床系列中得到证实,钙通道阻滞剂可能会在临床试验中作为放射保护剂进行测试。